Designing drugs with reversible activity

Designing drugs with reversible activity

News & Views

Published: 30 April 2024

Drug design

Nature Biotechnology

(2024)Cite this article

A strategy for creating drugs that can be quickly neutralized is demonstrated for anticoagulants.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

209,00 € per year

only 17,42 € per issue

Buy this article

Purchase on Springer LinkInstant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

Fig. 1: Schematic representation of DNA and PNA derivatives and their pharmaceutical applications.

References

Dockerill, M. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02209-z (2024).

Article 

Google Scholar 

Hirsh, J., Anand, S. S., Halperin, J. L. & Fuster, V. Circulation103, 2994–3018 (2001).

Article 
CAS 
PubMed 

Google Scholar 

Brenner, S. & Lerner, R. A. Proc. Natl Acad. Sci. USA89, 5381–5383 (1992).

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Melkko, S., Scheuermann, J., Dumelin, C. E. & Neri, D. Nat. Biotechnol.22, 568–574 (2004).

Article 
CAS 
PubMed 

Google Scholar 

Mannocci, L. et al. Proc. Natl Acad. Sci. USA105, 17670–17675 (2008).

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Gartner, Z. J. et al. Science305, 1601–1605 (2004).

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Clark, M. A. et al. Nat. Chem. Biol.5, 647–654 (2009).

Article 
CAS 
PubMed 

Google Scholar 

Barluenga, S. & Winssinger, N. Acc. Chem. Res.48, 1319–1331 (2015).

Article 
CAS 
PubMed 

Google Scholar 

Download references

Author information

Authors and Affiliations

Philogen SpA, Siena, Italy

Dario Neri

ETH Zürich, Zurich, Switzerland

Dario Neri

Corresponding author

Correspondence to
Dario Neri.

Ethics declarations

Competing interests

D.N. is co-founder, CEO and shareholder of Philogen, a biotech company that works (among other things) in the field of DNA-encoded chemical libraries.

About this article

Cite this article

Neri, D. Designing drugs with reversible activity.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02242-y

Download citation

Published: 30 April 2024

DOI: https://doi.org/10.1038/s41587-024-02242-y

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-024-02242-y

Exit mobile version